Kornimate/medical-research-clean huggingface dataset:
lactic acidosis during and after seizures

Conditions: Epilepsy

Summary: this project looks at the time course of lactic acid rise (if any) after seizures. salivary and capillary lactic acid are tested. this type of measurement may be useful in signalling the occurrence or recent history of a seizure.

lactic acid is released from cells during seizures and elevates lactic acid levels in blood and saliva. the time course of this rise is unknown. if lactic acid rises within a few minutes of a seizure, than it might be feasible to develop lactic acid sensors to provide notification of a recent seizure. this could lead to better safety monitoring for people with epilepsy. this study was designed to utilize a commercially available lactic acid sensor (investigators have no connection with the sensor manufacturer and purchased the device at list price) to measure salivary lactic acid levels after a seizure during inpatient video-eeg epilepsy monitoring.

Eligibility criteria:
inclusion criteria: 1. age 18-75 inclusive. 2. history of at least one generalized tonic-clonic (grand mal) seizure prior to enrollment in the study. 3. undergoing monitoring in the stanford epilepsy monitoring unit. exclusion criteria: 4. not pregnant. 5. inability to understand and sign the consent form. 6. no known history of mitochondrial disease or other metabolic disorders expected to affect blood lactate. 7. no known history of thrombophlebitis or excessive tendency to bleeding. not on coumadin. aspirin or anti-platelet agents are not an exclusion. 8. no known peripheral vascular disease affecting blood circulation to the fingers. 9. no painful peripheral neuropathy. 10. no raynaud's disease or phenomenon.

Keywords: epilepsy lactic acid saliva postictal
infrapatellar nerve block for post-operative knee arthroscopy pain control

Conditions: Internal Derangement of Knee

Summary: the purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy.

the purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy. randomized, double-blinded, placebo controlled, study.

Eligibility criteria:
inclusion criteria: * planned knee arthroscopy with soft tissue intervention * age 18+ * english speaking exclusion criteria: * contraindications to nerve block: eg neuropathy, type 1 diabetes, coagulopathy * knee arthroscopy with planned bony intervention

Keywords: infrapatellar nerve saphenous nerve knee arthroscopy nerve block
thyroid-associated ophthalmopathy subtypes and orbital antibodies

Conditions: Graves' Ophthalmopathy

Summary: the purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to graves' disease. the other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.


Eligibility criteria:
inclusion criteria: * graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy exclusion criteria: * pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision * age \< 18 years * inability to consent to participation in the study * pregnancy * history of radio-active iodine therapy
modulation of esophageal inflammation in barrett's esophagus by omega-3 fatty acids

Conditions: Barrett's Esophagus; Obesity

Summary: this study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in barrett's esophagus.


Eligibility criteria:
inclusion criteria * presence of be defined as ≥ 1 cm of visible columnar mucosa in the distal esophagus with intestinal metaplasia on histology. * absence of high grade dysplasia or eac on baseline histology. * bmi \> 30 kg/m2 or waist circumference \> 102 cm in men, \> 88 cm in women. * ability to give informed consent. exclusion criteria * allergy to ω3 ffas, fish or shellfish. * presence of high grade dysplasia or cancer on histology. * pregnant and or breastfeeding women * presence of esophagitis on initial endoscopy or symptoms of refractory gerd (heartburn or regurgitation ≥ 2 times a week) indicative of uncontrolled gastroesophageal reflux. * inability to give informed consent. * currently taking omega3 ffa as prescription. * anti-coagulant therapy (plavix, warfarin, coumadin) * ast or alt level \> three times upper limit of normal at baseline * ldl \> 200 mg/dl at baseline. * inr \> 2

Keywords: omega-3 fatty acid
a comparison study of the efficacy and tolerability of depakote er and depakote dr

Conditions: Mania; Mixed Mania

Summary: to compare the time to response, response rates, remission rates, and side effects in bipolar disorder inpatients treated with depakote er or depakote dr for acute mania or mixed mania.

there are several studies demonstrating the efficacy of divalproex in the acute treatment of mania and mixed mania. in fact, the american psychiatric associations practice guidelines for bipolar disorder recommends divalproex as a first-line treatment for acute mania and acute mixed mania; divalproex is the treatment of choice in the treatment of acute mixed mania. the food and drug administration (fda) approved divalproex for the acute treatment of mania in the 1990's. a new formulation, divalproex, depakote er, was recently fda approved for the treatment of epilepsy and prophylaxis of migraine headaches. in a pooled data analysis of nine open-labeled trials involving 321 epilepsy and bipolar disorder patients, smith et al. that depakote er was associated with superior tolerability including less frequent tremors, weight gain, and gastrointestinal complaints (all p\<0.001) compared with depakote dr. depakote er was preferred by subjects and it provided improved seizure control and a greater reduction in psychiatric symptoms.

Eligibility criteria:
inclusion criteria: * males and females between the ages 19-65 (inclusive). * dsm-iv diagnosis of acute mania or acute mixed mania . exclusion criteria: * dsm-iv diagnoses of bipolar disorder, depressed type, bipolar disorder rapid cycling type, major depressive disorder with psychotic features, schizoaffective disorder, schizophrenia, substance use disorder (active use within the last 3 months), or organic mood disorder. * history of a seizure disorder or an unstable physical disorder judged to significantly affect central nervous system function. * female subjects who are pregnant or of childbearing potential who are not using medically accepted means of contraception and female patients who are breastfeeding. * subjects who require antipsychotic medications because of severe psychosis and /or agitation. * subjects on antidepressants or mood stabilizers including lithium, oxcarbazepine, carbamazepine, and lamotrigine. * subjects who have failed previous trials with depakote dr or depakote er.
prospective study of tw in treatment of igan with asymptomatic abnormal urinalysis

Conditions: IgA Nephropathy

Summary: the purpose of this study is to: 1. to evaluate the latest effects of tw for iga nephropathy (igan) with asymptomatic abnormal urinalysis. 2. to evaluate the safety and tolerability of tw.

patients who fit the inclusion criteria will be randomly divided into three groups: tw group (tw at dosage of 90 mg/d), arb group (the control group, valsartan at dosage of 160 mg/d) and combined treatment group (tw at dosage of 60 mg/d and valsartan at dosage of 80 mg/d).

Eligibility criteria:
inclusion criteria: 1. 18-60 years old but no requirement for gender 2. all well fit the diagnostic criteria for primary igan and igan with asymptomatic abnormal urinalysis 3. informed consent is obtained from each research subject who agrees to conduct a periodic follow-up according to the research arrangement exclusion criteria: 1. secondary iga nephropathy, such as henoch-schönlein purpura nephritis, lupus nephritis and so on 2. some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis 3. severe infection 4. abnormality of liver function with glutamic pyruvic transaminase (gpt) or glutamic-oxal(o)acetic transaminase (got) more than twice upper limit of normal 5. women during pregnancy and lactation 6. patients need to procreation lately 7. patients treated with tw or arb within 4 months
a trial of 2% lidocaine gel for intrauterine device (iud) insertion

Conditions: Pain

Summary: the intrauterine device (iud) is a long-acting, highly effective, reversible contraceptive that may be underutilized due to fear of pain during insertion. although providers frequently prescribe non-steroidal anti-inflammatory drugs (nsaids) for iud insertion, there is no evidence for any pain reduction. in fact, no interventions evaluated in randomized controlled trials have been shown to be effective in reducing pain during iud insertion. while many women tolerate iud insertion well, others have moderate to severe pain. this double-blind randomized controlled trial of 150 women aims to estimate the efficacy of intracervical 2% lidocaine gel compared to placebo (ky jelly) to reduce iud insertion pain. our hypothesis is that women who are treated with 2% lidocaine gel prior to iud insertion will have reduced pain as measured on a 0 mm to 100 mm visual analog scale (vas). we will be able to detect a 15 mm difference on the vas with our sample size. other data to be collected include information regarding age, bmi, obstetric history, lactation status, time since pregnancy or delivery, last menstrual period, history of cervical conization, anxiety levels, anticipated pain levels, insertion characteristics (time, difficulty, complications), side effects, and satisfaction with pain control. if 2% lidocaine gel is effective, then a viable, easily administered option for pain control will be available to providers and patients.


Eligibility criteria:
inclusion criteria: 1. plans for iud insertion for contraception or abnormal uterine bleeding; 2. 18 to 49 years of age; 3. reached more than 6 weeks postpartum or 2 weeks postabortion if recently pregnant; 4. no prior iud use; 5. not taken analgesics or anxiolytics in the previous 24 hours; 6. not taken misoprostol prior to iud insertion; 7. the ability and are willing to give informed consent; 8. speaks english or spanish. exclusion criteria: 1. any contraindication to iud placement; 2. allergy to lidocaine or sensitivities to components of the lidocaine or placebo gel; 3. chronic narcotic/benzodiazepine/barbiturate use within the past year.

Keywords: pain measurement intrauterine devices lidocaine
producing increasingly complex themes using right-hemisphere engagement (picture) implemented with telemedicine

Conditions: Aphasia; Stroke

Summary: the investigators propose a pilot crossover trial of 2 behavioral language treatments, with randomized order of treatments and blinded assessors, to determine if a therapy designed to stimulate right hemisphere functions (producing increasingly complex themes using right-hemisphere engagement implemented with telemedicine - picture it; described below) is more effective in improving discourse than a published computer delivered lexical treatment (shown previously to improve naming) in subacute post-stroke aphasia.

the investigators will carry out a crossover study with randomized order of treatment conditions and blinded assessors, to compare changes in content and efficiency of discourse (primary outcome measures) from before treatment to immediately after treatment, to compare intervention focused on engaging the right hemisphere (picture it; see below) to a purely lexical treatment (see details below). secondary outcome measures will be: (1) changes in discourse from pre-treatment to 2 weeks post-treatment, and (2) changes in naming of objects and actions from immediately before treatment to immediately after treatment, and (3) changes in naming of objects and actions from pre-treatment to 2 months after both treatments. the investigators will also carry out resting state functional near infrared spectroscopy (fnirs) before and after each treatment to evaluate degree and location (e.g. intrahemispheric right versus left) of changes in connectivity associated with each treatment and with changes in each outcome measure. the investigators will also take saliva samples from participants who agree to this optional part of the study to determine the participants brain-derived neurotrophic factor status.

Eligibility criteria:
inclusion criteria: 1. diagnosis of aphasia secondary to stroke and presence of naming deficits (at least 20% errors on the boston naming test or hopkins action naming assessment) 2. capable of giving informed consent or indicating another to provide informed consent 3. age 18 or older 4. the stroke must have occurred between 1 month and 4 months prior to enrollment in the study or more than 6 months prior to enrollment in the study 5. able to understand therapy tasks (as indicated by 5 probes of each) exclusion criteria: 1. lack of english proficiency (by self/legally authorized representative report) 2. prior history of neurologic disease affecting the brain (e.g., brain tumor, multiple sclerosis, traumatic brain injury) other than stroke 3. prior history of severe psychiatric illness, developmental disorders or intellectual disability (e.g., ptsd, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders) 4. uncorrected severe visual loss or hearing loss by self-report and medical records
a placebo and active controlled study of ono-6950 following allergen challenge in patients with asthma

Conditions: Asthma

Summary: the primary objectives are * to determine the effect of ono-6950 200 mg qd versus placebo administered for 8 days on early asthmatic response (ear) and late asthmatic response (lar) induced by inhaled allergen * to determine the safety and tolerability of ono-6950 200 mg qd administered for 8 days in patients with asthma the secondary objectives are: * to compare the effect of ono-6950 versus montelukast on the % decrease of fev1 following allergen exposure, and * to determine the effect of ono-6950 versus placebo and montelukast on allergen-induced airway hyperresponsiveness (ahr) as measured by methacholine challenge

the study will examine if ono-6950 could alleviate ear and lar caused by an allergen challenge in subjects with asthma. patients will be required to have ear and lar after standardized allergen challenges during the screening. eligible patients will complete a randomized, double-blind, three-way crossover study. during each of three evaluation periods, patients will be administered either 200 mg ono-6950, 10 mg montelukast, or placebo for 8 days. each evaluation period will occur over 8 days and will include various assessments following allergen challenge and methacholine challenge. the study does not require an overnight stay at the clinical research center.

Eligibility criteria:
inclusion criteria: * patients of both genders, between 18 to 60 years of age, with bronchial asthma symptoms for at least 6 months * patients with fev1 ≥ 70% of predicted after withholding short-acting β agonists for at least 8 hours prior to testing * screening allergen challenge demonstrates that the patient experiences both an early and late asthmatic response * sensitivity to methacholine resulting in a ≥ 20% fall in fev1 (pc20 methacholine) * non-smokers with free from the usage of nicotine-containing products at least for a year prior to screening exclusion criteria: * previous history of life-threatening asthma, respiratory tract infection and/or exacerbation of asthma within 6 weeks prior to the first screening visit * past or present disorders and diseases including, but are not limited to, cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric, endocrine, or pulmonary other than asthma * significant safety laboratory, ecg, or vital sign abnormalities that would place the patient at undue disk during the study procedures * history of clinically significant multiple drug or food allergy

Keywords: asthma ono-6950 asthma in adult patients
mindfulness-based cognitive-behavioral therapy for gambling disorder

Conditions: Gambling Disorder

Summary: to compare two group psychological interventions for gambling disorder in terms of effectiveness and efficacy. one group is based in cognitive-behavioral therapy (tau) and the other group is based in tau with mindfulness-based relapse prevention (chawla, marlatt \& gordon, 2011). both interventions are composed by 14 weekly sessions, and follow-up to a month, three months, six months, one and two years.


Eligibility criteria:
inclusion criteria: * gambling disorder (dsm-5; apa, 2013). * 18 years or older. * males and females. exclusion criteria: * current psychosis or other severe/acute mental disorder. * current substance abuse. * intellectual disability. * under 18 years.
pediatric pelvic injuries - epidemiology and demography

Conditions: Pelvis Injury; Child, Only

Summary: a retrospective epidemiological study of pediatric pelvic injury from level 1 trauma centre. hypothesis: in the pediatric population, majority of pelvic injuries is of type a according to ao/ota (arbeitsgemeinschaft für osteosynthesefragen/orthopaedic trauma association) classification, the treatment is mostly conservative and complications of injury and treatment are less common than in adults.

study design: retrospective analysis (13 years), excluding pathological fractures. ao/ota type, epidemiological data, mode of treatment, and complications were recorded. data were analyzed using the fisher exact test and the wilcoxon test.

Eligibility criteria:
inclusion criteria of primary study group: * age ≤ 18 years * single pelvic bone fractures or pelvic ring injuries inclusion criteria of secondary study group: * age ≤ 18 years * combined pelvic and acetabular injuries * isolated fractures of the acetabulum exclusion criteria: * pathological fractures
effects of menthol in e-cigarettes on smoking behaviors

Conditions: Nicotine Dependence

Summary: the overall goal of this proposal is to understand the relationship between nicotine metabolism and menthol flavor in e-cigarettes on smoking behavior in smokers.


Eligibility criteria:
inclusion criteria: * at least 21 years of age * able to read and write english. * smoking at least 1 menthol cigarettes/cigars/little cigars per day * report regular menthol cigarette use * have at least 200ng/ml urine cotinine * willing to abstain from combustible tobacco products 12 hrs prior to each experimental session. * not planning a smoking quit attempt. * have not stopped use due to covid. * used e-cigarettes at least 10 times in the past six months. * fully vaccinated against covid-19. * must report history of juul and other nicotine salt/pod devices (i.e., juul-like) exclusion criteria: * use of psychoactive drugs including anxiolytics, antidepressants, and other psychostimulants unless prescribed and stable for two months. * current diagnosis of any severe psychiatric disorder * any significant current medical condition such as neurological, cardiovascular, endocrine, renal, pulmonary or hepatic pathology that would increase risk or would interfere with/mimic tobacco abstinence. * known hypersensitivity to propylene glycol and nut allergies. * pregnant or lactating females. * current criteria for moderate or severe cannabis and alcohol use disorder per dsm-5 criteria. * current criteria for other substance use disorders per dsm-5 criteria. * seeking treatment to stop smoking. * individuals who do not want to use e-cigarettes. * uncontrolled asthma (defined as \<20 on asthma control test) and/or endorsement of "yes" to environmentally induced bronchospasm that requires prescription epipen) * blood pressure \>170/\>100 and heart rate \>100 * vaping of cbd/thc or marijuana related products in the past 3 months * for current thc vapers: any report of mild or great evali-related symptoms (i.e. cough, shortness of breath, chest pain, nausea, vomiting, stomach pain, diarrhea, fever, chills, or weight loss) without non-evali reasonable and proximal cause
ketamine and morphine versus morphine alone for the treatment of acute pain in the emergency department

Conditions: Acute Pain

Summary: our goal is to study whether giving people low dose ketamine along with morphine when they come to the emergency department will help their pain more than giving morphine by itself. there have been many studies showing that low dose ketamine is safe and effective for pain control. ketamine is frequently used for pain control in ambulances and helicopters transporting injured patients to the hospital and has also been used for pain control in people who have just had surgery. the investigators would like to see if low dose ketamine would be safe and effective for patients with pain in the emergency department. patients are eligible for the study if they come to the emergency department and their treating physician decides to treat them with morphine (with certain exceptions such as pregnant patients and patients with eye injuries). they will be given information about participating in the study and if they agree, they will be given the study drug. the study drug will be either ketamine or salt water (saline). if patients continue to be in pain they will continue to receive doses of morphine just as they would if they were not in the study. if the treating physician feels that morphine alone is not enough, they will be free to choose another pain medication as they would normally.


Eligibility criteria:
inclusion criteria: * presenting to emergency department in acute pain * age 18 and over * determined to require morphine for pain control by treating physician exclusion criteria: * patients presenting with headache or head injury * patient with eye injury or eye pain * nontraumatic chest pain * pregnant patients or women of childbearing potential * patients allergic to morphine or ketamine * patients with known history of narcotic/alcohol abuse or presenting for narcotic medication refill * patients with hypertension: diastolic blood pressure \> 100 or systolic blood pressure \> 180 * patient whose pain is so severe that they are unable to give informed consent * patients who have had bad experiences to prior hallucinations from any origin

Keywords: ketamine acute pain